Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

Date: 
11 Nov 2015
Source: 
The Lancet Oncology
Audience: 
Professionals
Type of resource: 
Research

The prostate-specific antigen (PSA) test is used to screen for prostate cancer but has a high false-positive rate that translates into unnecessary prostate biopsies and overdiagnosis of low-risk prostate cancers. We aimed to develop and validate a model to identify high-risk prostate cancer (with a Gleason score of at least 7) with better test characteristics than that provided by PSA screening alone.